Study of the Subdermal Implant "Ultracol"
A Single-center Clinical Study of the Efficacy and Safety of the Medical Device "Intradermal Implant, Sterile ULTRACOL Based on Polydioxanone (ULTRA V Co., Ltd., Korea) in the Correction of Skin Contour Defects.
研究概览
地位
详细说明
The investigational product is composed of a mixture of polydioxanone and sodium carboxymethylcellulose. The polydioxanone content is as follows: Ultracol 200: 150 mg ±10%, Ultracol 100: 75 mg ±10%. The key difference from the closest analogs (AestheFill® V200, Sculptra™, Ellagen PLLA+CMC 1000 mg) is the presence of polydioxanone in the investigational product.
Thus, the analyzed analogues are not fully interchangeable medical products. The combined composition of Ultracol has not been studied properly. Therefore, during the clinical study, it is necessary to check the safety and effectiveness of a medical product with a combined composition - polydioxanone and sodium carboxymethylcellulose.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Russia
-
Moscow、Russia、俄罗斯、119034
- Estelab CLinic
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- The subject has indications for use according to the manufacturer instructions for the device.
- The subject is at least 18 years old at the time of signing the informed consent.
- The subject expresses willingness and ability to follow the requirements of the study protocol.
- The subject has no contraindications described in the device instructions for use.
Exclusion Criteria:
- The subject has at least one contraindication described in the device instructions for use, based on initial examination, laboratory tests and medical history.
- Women of reproductive age: pregnancy, planning pregnancy during the study period, or breastfeeding.
- Use of another product for the same indication during the clinical study.
- Participation in another clinical study.
- Pre-existing health problems that may compromise compliance with the study protocol.
- Patients prone to excessive scarring.
- Patients undergoing chemotherapy.
- Patients previously treated with intradermal fillers in the planned injection zone with persistent effect.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Experimental Group
ULTRACOL Intradermal Implant (Polydioxanone-based).
All 23 adult subjects (22 female, 3 male; mean age 51.1, range 37-70) received intradermal injections of ULTRACOL using linear-retrograde technique into the lower dermis or hypodermis.
ULTRACOL 100 (100 mg/vial, reconstituted in 1 mL water for injection) used in all 23 patients; ULTRACOL 200 (200 mg/vial, reconstituted in 2 mL water for injection) used in 20 patients.
Mean 1.87 injections per patient.
Maximum dose: 3 mL per procedure.
Treatment zones: nasolabial folds, cheeks, zygomatic area, perioral/periauricular regions, facial oval.
Follow-up: Day 30, 60, 160.
|
Lyophilized intradermal implant based on polydioxanone (PDO) and sodium carboxymethylcellulose (Na-CMC).
ULTRACOL 100: 100 mg/vial (75 mg PDO), reconstituted in 1 mL water for injection.
ULTRACOL 200: 200 mg/vial (150 mg PDO), reconstituted in 2 mL water for injection.
Administered intradermally using linear-retrograde technique.
Maximum dose: 3 mL per procedure.
Mean 1.87 injections per subject.
Manufactured by ULTRA V Co., Ltd., Republic of Korea.
Class III medical device.
Biostimulating mechanism: PDO hydrolysis stimulates neocollagenesis.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Wrinkle Severity Rating Scale (WSRS) Score
大体时间:Baseline, Day 30, Day 60, Day 160 after first injection
|
Validated 5-point scale (1 = no wrinkles, 5 = extreme wrinkles) assessed by the investigator.
A reduction of 1 or more points compared to baseline is considered clinically significant.
Units: Score on a scale (1-5).
|
Baseline, Day 30, Day 60, Day 160 after first injection
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Baker Ptosis Classification
大体时间:Baseline, Day 30, Day 60, Day 160 after first injection
|
4-grade classification of facial soft tissue ptosis assessed by the investigator (Grade I = minimal, Grade IV = severe).
Unit: Score on a scale (I-IV).
|
Baseline, Day 30, Day 60, Day 160 after first injection
|
|
Global Aesthetic Improvement Scale (GAIS) - Investigator Assessment
大体时间:Day 30, Day 60, Day 160 after first injection
|
5-point Global Aesthetic Improvement Scale (0 = worse, 1 = no change, 2 = improved, 3 = much improved, 4 = very much improved) assessed by the investigator.
Unit: Score on a scale (0-4).
|
Day 30, Day 60, Day 160 after first injection
|
|
Global Aesthetic Improvement Scale (GAIS) - Subject Self-Assessment
大体时间:Day 30, Day 60, Day 160 after first injection
|
5-point Global Aesthetic Improvement Scale (0 = worse, 4 = very much improved) assessed by the subject.
Unit: Score on a scale (0-4).
|
Day 30, Day 60, Day 160 after first injection
|
|
Change in Perceived Age (Subject Self-Assessment)
大体时间:Baseline, Day 30, Day 60, Day 160 after first injection
|
Subject self-assessment of perceived age before and after treatment.
A reduction of at least 1 year is considered clinically meaningful.
Unit: Years.
|
Baseline, Day 30, Day 60, Day 160 after first injection
|
|
Change in Skin Parameters by Multi-Parametric Ultrasound
大体时间:Baseline and Day 160 after first injection
|
Multi-parametric facial skin ultrasound assessing: epidermis thickness (mm), papillary dermis thickness (mm), reticular dermis thickness (mm), subcutaneous fat thickness (mm), vascularization index (%), dermis stiffness via compression elastography (kPa).
Unit: Combined imaging parameters reported per individual measurement (mm / % / kPa).
|
Baseline and Day 160 after first injection
|
|
Change in Lemperle Scale (Nasolabial Fold Depth)
大体时间:Baseline, Day 30, Day 60, Day 160 after first injection
|
5-point Lemperle scale for assessment of nasolabial fold depth (0 = no wrinkle, 5 = very deep wrinkle), assessed by the investigator.
Unit: Score on a scale (0-5).
|
Baseline, Day 30, Day 60, Day 160 after first injection
|
|
Number of Participants with Adverse Events (AEs) and Adverse Device Effects (ADEs)
大体时间:From first injection through Day 160 (160-day follow-up)
|
Frequency and severity of adverse events (AEs) and adverse device effects (ADEs), assessed by the investigator and recorded throughout the study.
Unit: Number of Participants.
|
From first injection through Day 160 (160-day follow-up)
|
|
Number of Participants with Serious Adverse Events (SAEs) and Serious Adverse Device Effects (SADEs)
大体时间:From first injection through Day 160 (160-day follow-up)
|
Frequency of serious adverse events (SAEs) and serious adverse device effects (SADEs), assessed by the investigator and recorded throughout the study.
Unit: Number of Participants.
|
From first injection through Day 160 (160-day follow-up)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.